Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality

Bone Marrow Transplant. 2016 May;51(5):725-7. doi: 10.1038/bmt.2015.315. Epub 2015 Dec 21.

Authors

Y Inoue^{1

2}, S Fuji^{1

2}, R Tanosaki³, T Fukuda¹

Affiliations

¹ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
² Juntendo University Graduate School of Medicine, Tokyo, Japan.
³ Blood Transfusion Division, National Cancer Center Hospital, Tokyo, Japan.

PMID: 26691420
DOI: 10.1038/bmt.2015.315

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Graft vs Host Disease / drug therapy
Graft vs Host Disease / mortality*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia-Lymphoma, Adult T-Cell / drug therapy
Leukemia-Lymphoma, Adult T-Cell / mortality*
Male
Middle Aged
Preoperative Period
Prognosis
Retrospective Studies
Time Factors
Transplantation, Homologous
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
mogamulizumab